237 related articles for article (PubMed ID: 35785664)
1. CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer.
Zheng X; Xu H; Lin T; Tan P; Xiong Q; Yi X; Qiu S; Yang L; Shen B; Ai J; Wei Q
Comput Biol Med; 2022 Aug; 147():105727. PubMed ID: 35785664
[TBL] [Abstract][Full Text] [Related]
2. IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer.
Yi X; Zheng X; Xu H; Li J; Zhang T; Ge P; Liao D; Li H; Lyu X; Ai J
Front Immunol; 2022; 13():898493. PubMed ID: 35812369
[TBL] [Abstract][Full Text] [Related]
3. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
[No Abstract] [Full Text] [Related]
4. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
[TBL] [Abstract][Full Text] [Related]
5. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
6. ACSM6 overexpression indicates a non-inflammatory tumor microenvironment and predicts treatment response in bladder cancer: results from multiple real-world cohorts.
Li Z; Yao Y; Qi T; Wu Z; Deng D; Liu B
Front Pharmacol; 2023; 14():1222512. PubMed ID: 37426827
[No Abstract] [Full Text] [Related]
7. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
Front Immunol; 2022; 13():965469. PubMed ID: 36090967
[TBL] [Abstract][Full Text] [Related]
8.
Zhao X; Hu J; Li J; Gu L; Chen J; Othmane B; Gong G; Yuan J; Deng H
Dis Markers; 2022; 2022():7147279. PubMed ID: 35909893
[TBL] [Abstract][Full Text] [Related]
9. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J
Front Immunol; 2021; 12():791924. PubMed ID: 34975891
[TBL] [Abstract][Full Text] [Related]
10. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
Zhang Y; Zhang X; Huang X; Tang X; Zhang M; Li Z; Hu X; Zhang M; Wang X; Yan Y
Stem Cell Res Ther; 2023 Feb; 14(1):15. PubMed ID: 36721217
[TBL] [Abstract][Full Text] [Related]
11. ACER2 forms a cold tumor microenvironment and predicts the molecular subtype in bladder cancer: Results from real-world cohorts.
Liu J; Cheng C; Qi T; Xiao J; Zhou W; Deng D; Dai Y
Front Genet; 2023; 14():1148437. PubMed ID: 36936425
[No Abstract] [Full Text] [Related]
12. FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer.
Xu PH; Chen S; Wang Y; Jin S; Wang J; Ye D; Zhu X; Shen Y
Comput Biol Med; 2023 Aug; 162():106976. PubMed ID: 37301098
[TBL] [Abstract][Full Text] [Related]
13. Eph receptor B6 shapes a cold immune microenvironment, inhibiting anti-cancer immunity and immunotherapy response in bladder cancer.
Jia X; Zhang D; Zhou C; Yan Z; Jiang Z; Xie L; Jiang J
Front Oncol; 2023; 13():1175183. PubMed ID: 37637034
[TBL] [Abstract][Full Text] [Related]
14. Identify the immune characteristics and immunotherapy value of CD93 in the pan-cancer based on the public data sets.
Guo A; Zhang J; Tian Y; Peng Y; Luo P; Zhang J; Liu Z; Wu W; Zhang H; Cheng Q
Front Immunol; 2022; 13():907182. PubMed ID: 36389798
[TBL] [Abstract][Full Text] [Related]
15. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis related genes mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide immunotherapy in bladder cancer.
Zhou L; Xu G; Huang F; Chen W; Zhang J; Tang Y
BMC Med Genomics; 2023 Apr; 16(1):88. PubMed ID: 37118734
[TBL] [Abstract][Full Text] [Related]
17. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma.
Li H; Zu X; Hu J; Xiao Z; Cai Z; Gao N; Chen J
Front Immunol; 2022; 13():964393. PubMed ID: 36211344
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia is correlated with the tumor immune microenvironment: Potential application of immunotherapy in bladder cancer.
Chen H; Zhang Y; Chen X; Xu R; Zhu Y; He D; Cheng Y; Wang Z; Qing X; Cao K
Cancer Med; 2023 Dec; 12(24):22333-22353. PubMed ID: 38063246
[TBL] [Abstract][Full Text] [Related]
19. 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer.
Hu J; Othmane B; Yu A; Li H; Cai Z; Chen X; Ren W; Chen J; Zu X
BMC Med; 2021 Nov; 19(1):289. PubMed ID: 34836536
[TBL] [Abstract][Full Text] [Related]
20. A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
Cai Y; Cheng Y; Wang Z; Li L; Qian Z; Xia W; Yu W
BMC Cancer; 2023 Aug; 23(1):725. PubMed ID: 37543645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]